所有图片(2)
About This Item
经验公式（希尔记法）:
C19H25N5O4 · HCl
CAS号:
分子量:
423.89
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推荐产品
品質等級
化驗
≥98% (TLC)
形狀
powder
顏色
white to off-white
溶解度
H2O: soluble 19.60-20.40 mg/mL, clear, colorless to faintly yellow
methanol: 20 mg/mL, clear, colorless
ethanol: 4 mg/mL
起源
Abbott
SMILES 字串
Cl[H].COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4
InChI
1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H
InChI 密鑰
IWSWDOUXSCRCKW-UHFFFAOYSA-N
基因資訊
human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)
一般說明
盐酸特拉唑嗪用于治疗高血压和良性前列腺增生（BPH）。它在肝脏中代谢。它可能与头晕、头痛和虚弱有关。盐酸特拉唑嗪与急性全身性皮疹性脓疱病有关。
應用
盐酸特拉唑嗪已通过反相色谱研究用于正交性和相似性分析5。此外，特拉唑嗪还用于评估化学计量学技术，以确定色谱方法中的正交性和相似性6。
生化／生理作用
α1-肾上腺素受体拮抗剂。
準備報告
盐酸特拉唑嗪可溶于水，浓度为19.60 - 20.40 mg/ml，并产生一种透明无色至淡黄色的溶液。它也可溶于乙醇，浓度为4 mg/mL。此外，根据需要加热，该产品可溶于甲醇，浓度为20 mg/mL，并产生澄清无色的溶液。
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
Terazosin in the treatment of benign prostatic hyperplasia
Brawer MK, et al.
Archives of Family Medicine, 2(9), 929-929 (1993)
Terazosin
Titmarsh S and Monk JP
Drugs, 33(5), 461-477 (1987)
A G Ramage et al.
European journal of pharmacology, 294(2-3), 645-650 (1995-12-29)
The effects of i.v. infusion of the alpha1-adrenoceptor antagonists doxazosin and terazosin (2 mg kg-1 h-1) on spontaneous hypogastric, renal and inferior cardiac nerve activity, spontaneous bladder contractions, blood pressure, heart rate and femoral arterial flow were investigated separately in
E Van Gyseghem et al.
Journal of pharmaceutical and biomedical analysis, 41(1), 141-151 (2005-12-15)
Several chemometric techniques were compared for their performance to determine the orthogonality and similarity between chromatographic systems. Pearson's correlation coefficient (r) based color maps earlier were used to indicate selectivity differences between systems. These maps, in which the systems were
R McCarty et al.
Hypertension (Dallas, Tex. : 1979), 27(5), 1115-1120 (1996-05-01)
To examine the contribution of the sympathetic nervous system to the development of hypertension, we injected spontaneously hypertensive rat (SHR) pups and normotensive Wistar-Kyoto rat (WKY) pups twice daily with saline (1.0 mL/kg SC) or terazosin (0.5 mg/kg SC), an
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门